HOME >> BIOLOGY >> NEWS
Pain killer fights breast cancer by targeting key enzyme

A painkilling medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.

The drug is called nimesulide. In laboratory experiments on breast cancer cells, scientists found that derivatives of nimesulide stopped the production of aromatase, the enzyme implicated in estrogen-dependent breast cancer. This form of breast cancer is the most common kind of breast cancer in postmenopausal women.

Aromatase converts hormones called androgens into estrogens, such as the hormone estradiol. Estrogen is a powerful mitogen an agent that causes cells to divide, and too much estrogen can cause cells to divide too quickly.

While many women with estrogen-dependent breast cancer take aromatase inhibitors to control their disease, the problem is that the current inhibitor drugs halt estrogen production throughout the body, said Robert Brueggemeier, a study co-author and a professor of medicinal chemistry and pharmacognosy and dean of the College of Pharmacy at Ohio State University.

"That means that other tissues, like bone and brain, which rely on normal aromatase production, may suffer," he said. "For one, we think that aromatase helps to maintain bone tissue throughout the postmenopausal period. Current aromatase inhibitors may disturb normal bone production there is some suggestion that these drugs may increase the risk of fractures."

The study's results suggest that nimesulide may block aromatase production only in breast tissue. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID), a drug that controls pain and inflammation. Studies of other NSAIDs, such as ibuprofen, have suggested that NSAIDs may reduce breast cancer incidence by 40 percent.

However, these drugs tend to halt aromatase production throughout the body.

Brueggemeier presented the work with Bin Su and Serena Landini, both graduate students in Ohio State's pharmacy pr
'"/>

Contact: Robert Brueggemeier
Brueggemeier.1@osu.edu
614-614-292-5711
Ohio State University
29-Mar-2006


Page: 1 2 3

Related biology news :

1. Aphids make chemical weapons to fight off killer ladybirds
2. Revealed -- Mosquito genes that could be controlling the spread of killer viruses
3. Common cancer gene sends death order to tiny killer
4. Bacteria show promise in fending off global amphibian killer
5. Antioxidant found in many foods and red wine is potent and selective killer of leukemia cells
6. Veterinary scientists explore poultry virus as cancer killer
7. Turning a cellular sentinel into a cancer killer
8. Cellular killer also important to memory
9. Painkillers may threaten power of vaccines
10. A new target for painkillers
11. Hope for major advance in fighting world killer disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2020)... ... , ... Shoreline Biome , a microbiome research company that develops tools ... will debut a novel new DNA isolation kit at the Miami Winter Symposium ... Prep kit, is a fast and easy-to-use kit designed for the efficient and unbiased ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has developed ... cells. The red blood cells are made utilizing a bioreactor that permits ... therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN ...
(Date:1/22/2020)... , ... January 21, 2020 , ... ... to lead the company’s new Business Development Department. The move, which is part ... had been previously serving as the company’s Senior Vice President where he oversaw ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... ... the exclusive distributor to food and beverage manufactures within North America. Both Lifecycle ... suppliers. This agreement will allow each company to pool their collective resources and ...
(Date:1/28/2020)... STATE COLLEGE, Pa. (PRWEB) , ... January 28, ... ... trusted line of Better Salivary Assay Kits . The new Salivary ... salivary bioscience research. “By measuring total immunoglobulin G in saliva, researchers can extend ...
(Date:1/27/2020)... ... January 27, 2020 , ... Valencell, ... financing from strategic investors led by Halma plc , a FTSE 100 ... TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma will ...
(Date:1/24/2020)... ... January 24, 2020 , ... The impact ... biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades of ... world. And as Slone Partners celebrates its 20th anniversary this year, ...
Breaking Biology Technology:
Cached News: